Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (241-250 of 310) with videos related to

Pageof 31
Sort By:
Blood|December 15, 1994
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study GroupR Hehlmann, H Heimpel, J Hasford, et al.
Onkologie|February 1, 1987
[Prospective controlled study of therapy of chronic myeloid leukemia (CML)]R Hehlmann, H Heimpel, D K Hossfeld, et al.
Leukemia & Lymphoma|January 1, 1993
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1R Hehlmann, H Heimpel, H J Kolb, et al.
Blood|September 25, 1999
Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangementsS Indraccolo, S Minuzzo, L Nicoletti, et al.
Leukemia|September 30, 2015
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaM Pfirrmann, M Baccarani, S Saussele, et al.
Leukemia|January 1, 1992
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study GroupR Hehlmann, H Heimpel, M Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapyM Schmidt, A Hochhaus, S A König-Merediz, et al.
Onkologie|February 1, 1991
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]R Hehlmann, H Heimpel, B Heinze, et al.
Leukemia|September 12, 2008
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in GermanyM Rohrbacher, U Berger, A Hochhaus, et al.
Leukemia|August 28, 2009
Harmonization of molecular monitoring of CML therapy in EuropeM C Müller, N C P Cross, P Erben, et al.
Pageof 31

Showing results (241-250 of 310) with videos related to

Sort By:
Pageof 31
Blood|December 15, 1994
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study GroupR Hehlmann, H Heimpel, J Hasford, et al.
Onkologie|February 1, 1987
[Prospective controlled study of therapy of chronic myeloid leukemia (CML)]R Hehlmann, H Heimpel, D K Hossfeld, et al.
Leukemia & Lymphoma|January 1, 1993
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1R Hehlmann, H Heimpel, H J Kolb, et al.
Blood|September 25, 1999
Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangementsS Indraccolo, S Minuzzo, L Nicoletti, et al.
Leukemia|September 30, 2015
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaM Pfirrmann, M Baccarani, S Saussele, et al.
Leukemia|January 1, 1992
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study GroupR Hehlmann, H Heimpel, M Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapyM Schmidt, A Hochhaus, S A König-Merediz, et al.
Onkologie|February 1, 1991
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]R Hehlmann, H Heimpel, B Heinze, et al.
Leukemia|September 12, 2008
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in GermanyM Rohrbacher, U Berger, A Hochhaus, et al.
Leukemia|August 28, 2009
Harmonization of molecular monitoring of CML therapy in EuropeM C Müller, N C P Cross, P Erben, et al.
Pageof 31